Marquette Asset Management LLC Purchases 46,369 Shares of Nuvation Bio Inc. (NYSE:NUVB)

Marquette Asset Management LLC boosted its position in shares of Nuvation Bio Inc. (NYSE:NUVB) by 70.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 111,759 shares of the company’s stock after buying an additional 46,369 shares during the period. Marquette Asset Management LLC’s holdings in Nuvation Bio were worth $169,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NUVB. SG Americas Securities LLC boosted its stake in Nuvation Bio by 921.4% during the third quarter. SG Americas Securities LLC now owns 110,226 shares of the company’s stock valued at $148,000 after buying an additional 99,434 shares during the last quarter. Clarius Group LLC bought a new position in Nuvation Bio during the third quarter valued at approximately $26,000. TD Asset Management Inc boosted its stake in Nuvation Bio by 100.0% during the third quarter. TD Asset Management Inc now owns 105,600 shares of the company’s stock valued at $142,000 after buying an additional 52,800 shares during the last quarter. Hsbc Holdings PLC boosted its stake in Nuvation Bio by 56.1% during the third quarter. Hsbc Holdings PLC now owns 174,827 shares of the company’s stock valued at $238,000 after buying an additional 62,844 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Nuvation Bio by 258.9% during the third quarter. Acadian Asset Management LLC now owns 113,717 shares of the company’s stock valued at $150,000 after buying an additional 82,031 shares during the last quarter. 61.67% of the stock is owned by institutional investors.

Nuvation Bio Trading Up 2.3 %

NUVB stock traded up $0.06 during midday trading on Friday, reaching $2.68. 638,805 shares of the company traded hands, compared to its average volume of 1,242,087. The business has a 50 day moving average of $2.58 and a 200-day moving average of $1.82. Nuvation Bio Inc. has a 52-week low of $0.95 and a 52-week high of $4.16.

Nuvation Bio (NYSE:NUVB) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04. Research analysts predict that Nuvation Bio Inc. will post -0.35 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on NUVB shares. Royal Bank of Canada increased their price target on Nuvation Bio from $4.00 to $5.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Wedbush restated an “outperform” rating and set a $5.00 price objective on shares of Nuvation Bio in a research report on Friday, March 1st. BTIG Research upgraded Nuvation Bio from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research report on Tuesday, March 26th. HC Wainwright upped their price objective on Nuvation Bio from $5.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, March 28th. Finally, Jefferies Financial Group upgraded Nuvation Bio from a “hold” rating to a “buy” rating and upped their price objective for the company from $1.40 to $10.00 in a research report on Wednesday, March 27th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $6.60.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.